The Antibody Humanization Market is evolving alongside advances in molecular biology, genetic engineering, and antibody discovery. Modern humanization methods are helping researchers adapt non-human antibodies for potential therapeutic and research applications.

CDR grafting remains an established approach in antibody humanization. In this method, important antigen-binding regions are transferred into a human antibody framework while attempting to preserve the original antibody's target recognition. Researchers may also use framework modification and resurfacing strategies depending on the characteristics of the antibody.

Phage display technology is another important tool in antibody engineering. It can support the selection and optimization of antibody candidates with desired binding characteristics. Transgenic animal technologies also provide alternative routes for generating antibodies with properties closer to human immune responses.

Computational tools are increasingly becoming part of antibody discovery and optimization workflows. In-silico analysis can assist researchers in evaluating antibody structures, predicting interactions, and identifying candidates for further laboratory investigation.

These technologies are helping reduce some of the limitations associated with conventional antibody development. Faster screening, improved characterization, and greater control over antibody design can support more efficient research programs.

As biotechnology companies continue investing in next-generation biologics, innovation in antibody engineering is expected to remain a central factor influencing the development of the global antibody humanization market.